E Mwinjiwa1, P Isaakidis2, R Van den Bergh2, A D Harries3, K D Bezanson4, T Beyene1, C Thompson5, M Joshua6, H Akello1, M van Lettow7. 1. Dignitas International, Zomba, Malawi. 2. Operational Centre Brussels, Operational Research Unit, Médecins Sans Frontières-Brussels, Brussels, Belgium. 3. Department of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK ; International Union Against Tuberculosis and Lung Disease, Paris, France. 4. Dignitas International, Zomba, Malawi ; Temmy Latner Centre for Palliative Care, Mount Sinai Hospital, Department of Family & Community Medicine, University of Toronto, Toronto, Ontario, Canada ; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 5. School of Medicine, University of Toronto, Toronto, Ontario, Canada. 6. Ministry of Health, Zomba Central Hospital, Zomba, Malawi. 7. Dignitas International, Zomba, Malawi ; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Abstract
SETTING: Antiretroviral treatment (ART) clinic at Zomba Central Hospital, Malawi. DESIGN: Retrospective analysis of records (2004-2011) of human immunodeficiency virus (HIV) infected patients with Kaposi's sarcoma (KS). OBJECTIVES: To determine the number and characteristics of HIV-infected adult patients with KS on ART and vincristine (VCR) therapy and their treatment outcomes. RESULTS: A total of 545 HIV-infected patients with KS (58% male, median age 33 years) were included in the study. The baseline median CD4 count was 180 cells/µl (interquartile range 111-287). Cumulative outcomes were as follows: 168 (31%) were still alive, 133 (24%) had died, 172 (32%) were lost to follow-up and 71 (13%) had transferred out; 229 had received at least one course of VCR, 171 had received less than one full course and 145 had not received VCR. The survival probability for 229 patients who received at least one course of VCR was 65% at 1 year, 42% at 2 years and 13% by 6 years. Patients who started VCR therapy before or concurrently with ART had a higher risk of death and generally a higher risk of death and loss to follow-up than those who started VCR after ART. CONCLUSION: Poor outcomes were noted in HIV-infected patients with KS in a programme setting in Malawi. Other treatment interventions, including combination and/or second-line chemotherapy and earlier ART initiation, are needed to reduce morbidity and mortality.
SETTING: Antiretroviral treatment (ART) clinic at Zomba Central Hospital, Malawi. DESIGN: Retrospective analysis of records (2004-2011) of human immunodeficiency virus (HIV) infectedpatients with Kaposi's sarcoma (KS). OBJECTIVES: To determine the number and characteristics of HIV-infected adultpatients with KS on ART and vincristine (VCR) therapy and their treatment outcomes. RESULTS: A total of 545 HIV-infectedpatients with KS (58% male, median age 33 years) were included in the study. The baseline median CD4 count was 180 cells/µl (interquartile range 111-287). Cumulative outcomes were as follows: 168 (31%) were still alive, 133 (24%) had died, 172 (32%) were lost to follow-up and 71 (13%) had transferred out; 229 had received at least one course of VCR, 171 had received less than one full course and 145 had not received VCR. The survival probability for 229 patients who received at least one course of VCR was 65% at 1 year, 42% at 2 years and 13% by 6 years. Patients who started VCR therapy before or concurrently with ART had a higher risk of death and generally a higher risk of death and loss to follow-up than those who started VCR after ART. CONCLUSION: Poor outcomes were noted in HIV-infectedpatients with KS in a programme setting in Malawi. Other treatment interventions, including combination and/or second-line chemotherapy and earlier ART initiation, are needed to reduce morbidity and mortality.
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Charles L M Olweny; Margaret Borok; Ivy Gudza; Jennifer Clinch; Mary Cheang; Clem F Kiire; Lorraine Levy; David Otim-Oyet; Joseph Nyamasve; Harvey Schipper Journal: Int J Cancer Date: 2005-02-10 Impact factor: 7.396
Authors: Jonathan A C Sterne; Margaret May; Dominique Costagliola; Frank de Wolf; Andrew N Phillips; Ross Harris; Michele Jönsson Funk; Ronald B Geskus; John Gill; François Dabis; Jose M Miró; Amy C Justice; Bruno Ledergerber; Gerd Fätkenheuer; Robert S Hogg; Antonella D'Arminio Monforte; Michael Saag; Colette Smith; Schlomo Staszewski; Matthias Egger; Stephen R Cole Journal: Lancet Date: 2009-04-08 Impact factor: 79.321
Authors: Agnes Moses; Albert Mwafongo; Maria Chikasema; Laureen Kafantenganji; Christopher Stanely; Emma Chimzukira; Coxcilly Kampani; Robert Krysiak; Satish Gopal; Nora E Rosenberg; Carol G Shores; Mina C Hosseinipour Journal: Malawi Med J Date: 2017-06 Impact factor: 0.875